Claudio Laudani Compares Aspirin and P2Y12 Inhibitor Monotherapy in ACS Patients After PCI
Claudio Laudani, Cardiovascular Disease Fellow UNICT, Post-Doc Research Scholar UFHealth JAX, shared a post on LinkedIn:
“Aspirin: another nail in the coffin? (For ACS)
In this systematic review and meta-analysis, we compared the relative benefits of aspirin and P2Y12 inhibitor monotherapy after a short DAPT in ACS patients undergoing PCI.
At interaction analysis, the benefits of short DAPT compared to standard DAPT appear to be driven by P2Y12 inhibitor monotherapy, rather than aspirin monotherapy.
Indeed, P2Y12 inhibitor monotherapy reduced NACE, any bleeding and major bleeding, while aspirin monotherapy retrieved neutral results.
At indirect comparison through network meta-analysis, P2Y12 inhibitor monotherapy reduced NACE by 23% and any bleeding by 32% compared to aspirin monotherapy.
Finally, more robust and high quality evidence exist for P2Y12 inhibitor monotherapy, especially ticagrelor, and our trial sequential analysis reflected this result.”
Read the full article here.
Article: Aspirin or P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention for Acute Coronary Syndromes
Authors: Claudio Laudani, Daniele Giacoppo, Giovanni Occhipinti, Mattia Galli, Antonio Greco, Marco Spagnolo, Luis Ortega-Paz, Francesco Costa, Dominick J. Angiolillo, Davide Capodanno
Stay updated on all scientific advances in the field with Hemostasis Today.
-
Mar 12, 2026, 16:22Augustina Isioma Ikusemoro: Quality Indicators in Processed Blood Components
-
Mar 12, 2026, 16:20Aryabhatta Sadhu: The Full Spectrum of Transplant Immunology and Clinical Care
-
Mar 12, 2026, 16:17Megan Adediran: Building Pathways to Sustainable Care for People With Bleeding Disorders in Nigeria
-
Mar 12, 2026, 16:09Rob Mac Sweeney: Hemodynamic Failure During Sepsis
-
Mar 12, 2026, 16:06Haroun Gajraj: Shortwave Diathermy for Facial Spider Veins
-
Mar 12, 2026, 12:05Kent H: The Lymphatic System – The Unsung Hero of Detox
-
Mar 12, 2026, 11:55Akinchan Bhardwaj: Exercise Biological Modifier of Vascular Trajectory
-
Mar 12, 2026, 11:50Guy Young: Clinical Conversations on Gene Therapy Progress in Hemophilia B at THSNA 2026
-
Mar 12, 2026, 11:44Yves Bikorimana: Causes, Diagnosis, and Management of Neonatal Alloimmune Thrombocytopenia